Pfizer to drop $74M for COVID cough-screening smartphone app developer

As Pfizer plans to lean in on producing its COVID-19 antiviral this year—boosting the number of available Paxlovid treatments by 50% to more than 3.6 billion doses by the end of 2022—the drugmaker is looking to pick up the developer of a diagnostic smartphone app, which could help get tablets into patients’ hands faster.